An Open-label, Multicenter Study to Assess the Safety of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease Who Completed C87035 (NCT00899678) or Who Were Terminated From C87035
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007914/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the long-term safety and tolerability of
certolizumab pegol (CZP) treatment in children and adolescents with moderately to severely
active Crohn's disease. Secondarily, to assess the long-term efficacy, pharmacokinetics (PK),
and immunogenicity of CZP treatment in children and adolescents with moderately to severely
active Crohn's disease.
提供机构：
Vivli
创建时间：
2022-06-17
